Gynesonics Announces New York Medicaid Coverage for CPT Code 58580, Transcervical Radio Frequency Ablation of Uterine Fibroids
17 déc. 2024 09h00 HE
|
Gynesonics
REDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Gynesonics Inc., a medical device company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, is...
Gynesonics Announces New SMART OS™ Software Technology for Sonata® System Treatment of Uterine Fibroids
26 sept. 2024 08h30 HE
|
Gynesonics
REDWOOD CITY, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Gynesonics Inc., a medical device company focused on the development of minimally invasive solutions for symptomatic uterine fibroids,...
Gynesonics Announces Key Executive Appointments to Further Accelerate and Expand Adoption of the Sonata Treatment
19 mars 2024 10h00 HE
|
Gynesonics
Gynesonics announces key executive appointments to further accelerate and expand adoption of the Sonata Treatment.
Gynesonics’ Incision-Free Sonata Procedure for the Treatment of Uterine Fibroids Reaches Patient Milestones in the U.S. and Globally
17 oct. 2023 12h00 HE
|
Gynesonics
Gynesonics' Sonata® Procedure has been used to treat over 1,000 women in the United States and approximately 6,500 women globally.